Skip to main content
Eligibility
for people ages 18 years to 99 years
Location
at San Francisco, California and other locations
Dates
study started
estimated completion:
Principal Investigator

Description

Summary

The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).

Official Title

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

Details

This is a multicenter, open-label, dose-escalation, and dose expansion study of MEDI4736 in combination with tremelimumab to evaluate the safety, tolerability, pharmacokinetic (PK), immunogenicity, and antitumor activity of MEDI4736 in combination with tremelimumab in adult subjects with advanced NSCLC.

Keywords

NSCLC Non-small Cell Lung Cancer Lung Cancer anti-CTLA-4 anti-PD-L1 immunotherapy IMTC Antibodies, Monoclonal Tremelimumab

Eligibility

You can join if…

Open to people ages 18 years to 99 years

  1. Age ≥ 18 years
  2. Advanced non-small cell lung cancer
  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  4. Adequate organ and marrow function

You CAN'T join if...

  1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
  2. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs
  3. Active or prior documented autoimmune disease within the last 2 years.

Locations

  • Research Site
    San Francisco, California, USA
  • Research Site
    Los Angeles, California, USA

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
MedImmune LLC
ID
NCT02000947
Phase
Phase 1/2
Lead Scientist
Thierry Jahan
Study Type
Interventional
Last Updated
January 2017